Connect with us

National

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies – News-Medical.Net

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-ca…

Published

on

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy.  While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.
According to WHO reports, the current COVID-19 (coronavirus disease 2019) pandemic has caused more…

Click here to view the original article.

Safety Mate